FDA Advisory Committee Votes to Recommend Six Peptides for Compounding

At its July 23-24, 2026 meeting, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted to recommend six of the seven peptides it reviewed for addition to the 503A bulks list: BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. Emideltide (a delta sleep-inducing peptide analog) was the lone compound the committee did not recommend.

The 503A bulks list matters because it determines which bulk substances traditional compounding pharmacies may use for patient-specific compounded prescriptions. A recommendation to add these peptides is a meaningful step toward reopening a lawful, physician-supervised compounding pathway.

• Recommended for the 503A bulks list: BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon.
• Not recommended: Emideltide.
• The votes were close, and the committee’s recommendation went against the FDA’s own scientific reviewers, who had advised against all seven.

A PCAC recommendation is advisory, not a final decision. Permanent additions to the bulks list require notice-and-comment rulemaking, and the agency is not required to follow the committee’s recommendation. An interim enforcement policy is a separate route: on October 28, HHS announced a draft policy for certain peptides while that rulemaking proceeds. Its implementation timing and conditions need confirmation.

It is also important to keep the framing precise: adding a peptide to the 503A bulks list is about compounding eligibility, not FDA approval of a finished drug. We are hopeful that clearer guidance for 503B outsourcing facilities may follow, but that is a separate track that has not been decided.

For patients and clinicians who have been following this issue, the takeaway is cautious optimism. The regulatory door that closed in 2023 is now closer to reopening for six of the most closely watched peptides, through legitimate compounding channels rather than the gray market.

GobyPeptides will keep tracking the rulemaking timeline and update each peptide page as the FDA acts. Join the waitlist to be notified as lawful access develops through the GobyMeds care pathway.